New Study Analyzes Twenty Years of Treatment and Research by James R. Berenson, MD
Study to examine how Dr. Berenson’s patients survive three times longer than the National Average to be led by volunteer team of computer data scientists, researchers and academicians under the direction of Oracle VP of Development, Kash Mohammadi
A team of computer data scientists, researchers and academicians has volunteered to work with IMBCR and its researchers on a new initiative that will help multiple myeloma patients achieve the best outcomes for their treatments. With the use of computer modeling for this in-depth analysis of data, generated from a large population of myeloma patients, the team hopes to identify ways to optimize therapies for patients with this bone-marrow based cancer.
Multiple myeloma is a cancer of plasma cells and is a type of white blood cell found in bone marrow. These cells normally make proteins called antibodies to help fight off infection. When the myeloma cells become cancerous they multiply and can lead to abnormally high levels of proteins in the bloodstream that can cause bone, immune system, kidney and red blood cell count health related problems.
Kash Mohammadi, Vice President of Development for Oracle Corporation, and project spearhead comments, “Dr. Berenson has been treating this disease for more than thirty years and the life expectancy of his patients is three times the average. He has reviewed twenty years of clinical data and now, for the first time, we have a detailed numerical glimpse into his methods and his results. We intend to use every technique and technology available to analyze this data and find out what makes his techniques so effective.”
James R. Berenson, MD, President and Chief Medical Officer for IMBCR added, “We will be analyzing data from myeloma patients that will include their personal demographics. It will also provide the characteristics of their particular form of myeloma, as well as detail responses to specific patient’s treatments.”
The team hopes that by thoroughly analyzing the specific types of myeloma, along with patient characteristics, their responses and the side effects of different treatments, they will be able to achieve and establish guidelines for better outcomes, not only in terms of responsiveness, but also be able to help optimize the quality of life for patients undergoing various treatments.
IMBCR’s innovative research on multiple myeloma has already led cancer patients to greater longevity and an improved quality of life, due to their expanded drug therapy options and treatment combinations;
The Institute for Myeloma & Bone Cancer Research is an independent, non-profit cancer research organization, located in Los Angeles, dedicated to more effective treatment, and ultimate cure, for myeloma and bone cancer. IMBCR’s innovative research provides cancer patients with greater longevity and an improved quality of life. With the use of expanded drug therapy options and treatment combinations, IMBCR provides patients with an opportunity to enhance their chances of surviving cancer and to overcome one of the hardest challenges of their lives.
About Dr. Berenson, MD:
James R. Berenson, MD is the founder, President and Medical and Scientific Director of the Institute for Myeloma & Bone Cancer Research, and
President of James R. Berenson, MD, Inc. a medical practice specializing in multiple myeloma and metastatic bone disease. He is also President of Oncotherapeutics, http://www.oncotherapeutics.com/
For more information, please visit http://www.imbcr.org or call 310-623-1210
John M. Forrester